While Novo Nordisk blamed rival drugs and its own tepid expansion for downgrades to sales and profit growth, some analysts ...

Investors knocked $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 sales.

Medical bottles and a syringe are seen with the Novo Nordisk logo displayed on a screen in the background.

As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for the GLP-1 (glucagon-like ...